JP7588537B2 - Drug administration device - Google Patents

Description

The present invention relates to a drug administration device that administers a drug to a subject such as a living body.

There is a known treatment method for continuously administering a medicinal liquid into the body of a patient. For example, one known treatment method for diabetic patients is to continuously administer a small amount of insulin into the body. This treatment method uses a portable medicinal liquid administration device that can be fixed to the user's body or clothing and carried around. Using a portable medicinal liquid administration device, it is possible to administer medicinal liquid to the user throughout the day. One known example of this type of medicinal liquid administration device is an insulin pump that administers insulin to the user.

As one of the portable drug solution administration devices mentioned above, a drug solution administration device has been proposed that has a syringe-shaped reservoir in which the drug solution is stored, and a plunger that serves as a drive unit for discharging the drug solution from the reservoir. In the drug solution administration device, a cannula is liquid-tightly connected to a liquid delivery tube extending from the reservoir, and this cannula is placed under the skin of the user, and the drug solution stored in the reservoir is administered into the user's body.

Patent Document 1 describes a technology in which a needle member (liquid delivery hole) having a needle tube for liquid delivery is provided at the tip of the liquid delivery tube, a rubber partition (rubber stopper) is provided at a connection port having a cannula, and the liquid delivery hole is punctured and inserted into the rubber stopper, thereby connecting the liquid delivery tube and the cannula.

European Patent No. 1951340

The technology described in Patent Document 1 had the following problems. A drug solution administration device such as an insulin pump comprises a device body and a cradle that are detachable from each other. The cradle is attached and fixed to the user's skin, and the device body is detachable from the cradle. The above-mentioned syringe, plunger, liquid delivery tube, and liquid delivery hole are provided on the device body, and the above-mentioned connection port is provided on the cradle. When the device body is attached to the cradle, the liquid delivery hole is punctured into the rubber stopper, and the device body is rotated (pivoted) around the punctured part to attach it to the cradle.

However, when using the drug solution administration device, for some reason, such as when the user takes a bath or when filling the reservoir with drug solution, the device body needs to be removed from the cradle. The device body then needs to be reattached to the cradle. For this reason, the device body and the cradle are repeatedly attached and detached while the drug solution administration device is in use, and the liquid delivery hole, which has a puncture end that can be inserted into the rubber stopper, is punctured and removed the same number of times as this is repeated. As a result, for example, the puncture hole in the rubber stopper may widen or the rubber stopper itself may be damaged, which could cause the drug solution to leak from the connection between the rubber stopper and the liquid delivery hole. In particular, the device disclosed in Patent Document 1 rotates and moves the device body in a punctured state to be attached to the cradle, so the rubber stopper is easily damaged by the liquid delivery hole.

The device disclosed in Patent Document 1 is often attached to the abdomen or back of the user. The attachment location and orientation of the device are changed depending on the condition of the user's skin and subcutaneous tissue on that day. For this reason, the user may attach the pump in the wrong direction. For example, when attaching the device body to the cradle, moving the device body in the wrong direction may damage the rubber stopper due to the liquid delivery hole. This may cause deterioration of the rubber stopper, which may lead to liquid leakage while the drug administration device is in use.

At least one embodiment of the present invention has been made in consideration of the above circumstances, and specifically aims to provide a drug solution administration device that can prevent leakage of drug solution from the connection port due to repeated attachment and detachment of the device body and the cradle.

The drug solution administration device of this embodiment comprises a device body having a reservoir for storing the drug solution, a liquid delivery drive unit for delivering the drug solution from the reservoir, a liquid delivery tube through which the drug solution delivered from the reservoir flows, and a liquid delivery hole communicating with the liquid delivery tube, a support surface portion on which the bottom portion of the device body is placed, and a cradle to which a connection port for holding a cannula to be inserted into a living body is attached and which is attached to the living body, wherein the liquid delivery hole and the connection port are detachably fluidly connected, and the support surface portion has a shape complementary to the bottom portion, and the cradle is provided with a guide member for guiding the rotational movement of the device body in the mounting direction .

According to at least one embodiment of the present invention, it is possible to prevent leakage of medicinal liquid from the connection port due to repeated attachment and detachment of the device body and the cradle.

1 is a schematic perspective view of a drug solution administration device according to a first embodiment. FIG. 1 is a schematic exploded perspective view of a drug solution administration device according to a first embodiment; 1 is a schematic partial perspective view of a drug solution administration device according to a first embodiment, seen from the bottom side; 1 is a schematic side view of a drug solution administration device according to a first embodiment. FIG. FIG. 2 is a schematic perspective view of a cradle of the drug solution administration device according to the first embodiment. 1 is a schematic perspective view showing a procedure for using the drug solution administration device according to the first embodiment. FIG. 1 is a schematic perspective view showing a procedure for using the drug solution administration device according to the first embodiment. FIG. 1 is a schematic perspective view showing a procedure for using the drug solution administration device according to the first embodiment. FIG. FIG. 11 is a schematic exploded perspective view of a drug solution administration device according to a second embodiment. FIG. 11 is a schematic perspective view of a drug solution administration device according to a second embodiment, as viewed from the bottom side. FIG. 11 is a schematic perspective view of a cradle of a drug solution administration device according to a second embodiment. FIG. 11 is a schematic side view showing a mounting method of the drug solution administration device according to the second embodiment. FIG. 11 is a schematic side view showing a mounting method of the drug solution administration device according to the second embodiment. 13 is a schematic perspective view showing a procedure for using the drug solution administration device according to the second embodiment. FIG. 13 is a schematic perspective view showing a procedure for using the drug solution administration device according to the second embodiment. FIG. 13 is a schematic perspective view showing a procedure for using the drug solution administration device according to the second embodiment. FIG. 13 is a schematic perspective view showing a procedure for using the drug solution administration device according to the second embodiment. FIG. FIG. 13 is a schematic perspective view of a drug solution administration device according to a modified example. 13 is a schematic perspective view showing a procedure for using a medical solution administration device according to a modified example. FIG. 13 is a schematic perspective view showing a procedure for using a medical solution administration device according to a modified example. FIG. 13 is a schematic perspective view showing a procedure for using a medical solution administration device according to a modified example. FIG.

The following describes in detail the embodiments of the present invention with reference to the drawings. The embodiments shown here are merely illustrative in order to embody the technical ideas of the present invention, and do not limit the present invention. Furthermore, all other possible embodiments, examples, and operational techniques that can be conceived by those skilled in the art without departing from the gist of the present invention are included in the scope and gist of the present invention, and are included in the scope of the inventions described in the claims and their equivalents.

Furthermore, for the convenience of illustration and ease of understanding, the drawings attached to this specification may be represented diagrammatically with appropriate changes in scale, aspect ratio, shape, etc. from the actual product, but these are merely examples and do not limit the interpretation of the present invention.

In the following explanation, when ordinal numbers such as "first" and "second" are used, they are used for convenience and do not dictate any particular order, unless otherwise specified.

For ease of explanation, the XYZ coordinate system is set as shown in the figure in this specification. That is, the "Z direction" is the direction along the vertical direction, the "X direction" is a direction perpendicular to the Z direction and parallel to the horizontal plane, and the "Y direction" is another direction perpendicular to the Z direction and parallel to the horizontal plane (direction perpendicular to the X direction). Therefore, in the drug solution administration devices 100 and 110 according to this embodiment, the Z direction coincides with the thickness direction (up-down direction) of the device, the X direction coincides with the longitudinal direction (front-rear direction) along the axial direction of the device, and the Y direction coincides with the transverse direction (width direction) perpendicular to the longitudinal direction of the device.

The drug solution administration device 100, 110 according to the present embodiment is a device for continuously administering a drug solution into the body of a user. Examples of drug solutions administered using the drug solution administration device 100, 110 include insulin, analgesics, anticancer drugs, HIV (Human Immunodeficiency Virus) drugs, iron chelating drugs, and pulmonary hypertension drugs. In the present embodiment, a portable insulin pump that administers insulin into the body of a user is assumed as an example of the drug solution administration device 100, 110. The drug solution administration device 100, 110, which is an insulin pump, is used by attaching it to the surface of a living body. The surface of a living body is typically the surface of the user's skin. The position where the drug solution administration device 100, 110 is attached is, for example, the abdomen of the user.

[First embodiment]
FIG. 1 is a schematic perspective view showing the appearance of a drug solution administration device 100 according to a first embodiment, and FIG. 2 is a schematic exploded perspective view showing a main part of the overall configuration of the drug solution administration device 100. As shown in FIG.

<Configuration>
As shown in Figures 1 and 2, the drug solution administration device 100 generally comprises a first main body portion 10 which holds a reservoir 12 in which the drug solution is stored, a second main body portion 20 which holds a liquid delivery drive unit 23 for delivering the drug solution in the reservoir 12 into a living body, and a cradle 30 which holds a cannula 50 and is attached to the surface of the living body.

The first body part 10 is a disposable part. The second body part 20 is a reusable part. The first body part 10 and the second body part 20 are separable from each other and can be connected to each other. In addition, the cradle 30 constitutes the drug solution administration device 100 together with the device main body 101 in which the first body part 10 and the second body part 20 are connected.

<First main body part>
The first main body 10 includes a housing 11, a reservoir 12, an extrusion unit 13, a liquid supply tube 14, and a power supply unit 15. The housing 11 is formed in a substantially rectangular shape in a plan view (Z direction view). The housing 11 is also a substantially rectangular parallelepiped that is open at the top.

2, the housing 11 has a flat bottom surface portion 11a and a side wall portion 11b that rises around the entire outer periphery of the bottom surface portion 11a. The bottom surface portion 11a is a plate portion that divides the housing 11 in the Z direction. When the device main body 101 is attached to the cradle 30, the bottom surface portion 11a is disposed opposite the cradle 30. The reservoir 12, extrusion portion 13, liquid delivery tube 14, and power supply portion 15 are attached to the surface of the bottom surface portion 11a facing the second main body portion 20 (the upper surface of the bottom surface portion 11a). The bottom surface portion 11a also functions as the bottom surface portion 101a of the device main body 101 in which the second main body portion 20 is attached to the first main body portion 10.

The housing 11 includes a first storage section 11c surrounded by a bottom section 11a and a side wall section 11b. The first storage section 11c is a space provided on the upper side of the bottom section 11a, and contains a reservoir 12, a power supply section 15, and the like. When the cover 21 of the second main body section 20 is connected to the housing 11, the liquid delivery drive section 23 attached to the inside of the cover 21 is contained within the first storage section 11c.

The housing 11 includes a first mounting portion 11d for engaging with a second mounting portion 31c of the cradle 30 described later when the device main body 101 is mounted on the cradle 30 to maintain the mounted state of the device main body 101 and the cradle 30. The first mounting portion 11d is an engagement recess provided on the outer surface of the side wall portion 11b along the Y direction of the first main body portion 10. As shown in FIG. 3, the first mounting portion 11d is disposed in a position facing the second mounting portion 31c with respect to each of the two side wall portions 11b (i.e., the side wall portions 11b on the short sides) along the Y direction when the device main body 101 is mounted on the cradle 30. The pair of first mounting portions 11d may be provided on two side surfaces facing each other in the X direction among the outer surfaces of the side wall portions 11b. Similarly, the pair of second mounting parts 31c are provided on the mounting surface 31a of the cradle 30, which will be described later, at locations corresponding to the positions of the first mounting parts 11d when mounting is complete.

The first mounting part 11d and the second mounting part 31c function as mounting parts that stably maintain the mounting state between the device body 101 and the cradle 30. Therefore, when the device body 101 is mounted on the cradle 30, the drug solution administration device 100 can stably maintain the mounting state. It is preferable that the first mounting part 11d and the second mounting part 31c are configured as mounting parts that are locked when the device body 101 moves in the mounting direction D1. This mounting can be released by releasing the claw of the second mounting part 31c that has entered the first mounting part 11d. The structure and method of the mounting parts can be changed as appropriate.

The bottom surface 11a is composed of a first bottom surface 11e, a second bottom surface 11f, and a first step portion 11g. The first bottom surface 11e and the second bottom surface 11f are plate surfaces extending along the X direction. As an example, the first bottom surface 11e is disposed on the bottom surface portion 11a in the mounting direction D1 of the device main body 101, and the second bottom surface 11f is disposed on the bottom surface portion 11a in the direction (dismounting direction D2) in which the mounting state of the device main body 101 is released. As shown in FIG. 3, the first bottom surface 11e and the second bottom surface 11f are positioned at different levels in the thickness direction (Z direction) of the housing 11, and the second bottom surface 11f is positioned lower (on the living body surface side) than the first bottom surface 11e. When the device main body 101 is placed on the cradle 30, the first bottom surface 11e is placed on the first mounting surface 31e of the mounting surface portion 31a. The second bottom surface 11f is placed on the second mounting surface 31d of the mounting surface portion 31a when the device main body 101 is placed on the cradle 30.

Here, the "mounting direction D1" is a direction approximately parallel to the mounting surface 31a (i.e., approximately parallel to the surface of the living body) for rotating the device body 101 when mounting the device body 101 on the cradle 30 (see FIG. 5). By rotating the device body 101 in the mounting direction D1 around the engagement position between the engagement recess 17 of the device body 101 and the connection port 40 provided on the cradle 30 (more specifically, the puncture position of the liquid delivery hole 16 relative to the plug 43) as the center of rotation, the bottom surface 101a (bottom surface 11a) of the device body 101 can be moved above the mounting surface 31a of the cradle 30.

The "detachment direction D2" is the opposite of the attachment direction D1 and is a direction approximately parallel to the placement surface 31a (i.e., approximately parallel to the surface of the living body) for rotating the device body 101 when removing it from the cradle 30 (see FIG. 5). The device body 101 can be moved to a position away from above the placement surface 31a of the cradle 30 by rotating the device body 101 in the attachment removal direction D2 around the engagement position between the engagement recess 17 of the device body 101 and the connection port 40 provided on the cradle 30 as the center of rotation. After rotating in the attachment removal direction D2, the device body 101 can be lifted upward to release the engagement between the engagement recess 17 and the connection port 40, and completely removed from the cradle 30.

The first step portion 11g is provided at the boundary portion that divides the first bottom surface 11e and the second bottom surface 11f. The first step portion 11g is a step on the mounting surface portion 31a that extends along the X direction on the bottom surface portion 11a. As shown in FIG. 4, when the first main body portion 10 is viewed from the side (viewed in the X direction), the first step portion 11g has a step surface that rises in a substantially vertical direction (Z direction) from the first bottom surface 11e to the second bottom surface 11f. That is, in the use state of the drug solution administration device 100, the second bottom surface 11f extends parallel to the body surface at a position closer to the body surface than the first bottom surface 11e. When the device main body 101 is attached to the cradle 30, the first step portion 11g abuts against the step surface of the second step portion 31f of the cradle 30 to become a restricting portion that restricts the rotational movement of the device main body 101.

In addition, the bottom surface portion 11a is formed to have a shape complementary to the mounting surface portion 31a of the cradle 30 when the attachment of the device body 101 and the cradle 30 is complete. In other words, when the bottom surface portion 11a and the mounting surface portion 31a are connected, they are configured to complement each other's shapes over at least one axial direction of the drug solution administration device 100. Therefore, the configuration of the bottom surface portion 11a is not limited to the configuration described above. More specifically, when the attachment of the device body 101 and the cradle 30 is complete, the mounting surface portion 31a has an abutment surface that restricts the movement of the device body 101 in the attachment direction, and the device body 101 has a surface on the bottom surface portion 11a that faces the abutment surface. The bottom surface 11a and the mounting surface 31a may have at least a partially complementary structure, and preferably, in a plan view of the drug solution administration device 100, the D1 side of the engagement recess 17 and the connection port 40, or the corner side facing the corner where the engagement recess 17 and the connection port 40 are arranged, have a complementary structure. That is, the surface that abuts when the device body 101 is completely attached to the cradle 30 is provided on the mounting surface 31a, and in the completely attached state, the abutting surface conforms to the shape of the bottom surface 11a in any of the X, Y, and Z directions. In addition to the abutting surface that restricts movement, the bottom surface 11a and the mounting surface 31a can be appropriately provided with structures such as switches, notches, and latches that are necessary for the function and manufacture of the drug solution administration device 100.

The reservoir 12 includes an outer cylinder 12a in which the medicinal liquid to be administered to the user is stored, and the medicinal liquid in the outer cylinder 12a is discharged by the pressing action of the extrusion unit 13. The reservoir 12 is provided with a medicinal liquid discharge port (not shown) at the tip, and one end of the liquid supply tube 14 is connected to this discharge port. The other end of the liquid supply tube 14 is connected to the liquid supply hole 16 (see FIG. 3) from the first storage unit 11c side of the housing 11. The reservoir 12 is provided with a gear 12b near the end. The gear 12b rotates by receiving the driving force of the liquid supply drive unit 23. The end of the rotation shaft of the gear 12b is engaged with the feed screw 12c. The feed screw 12c is provided so as to be movable in the X direction. The reservoir 12 moves the extrusion unit 13 in the X direction while the gear 23b and the gear 12b rotate due to the drive of the liquid supply drive unit 23, and the feed screw 12c rotates according to the rotation of the gear 12b. The liquid medicine in the reservoir 12 is delivered to the liquid delivery tube 14 according to the amount of pressure applied to the extrusion part 13, which moves as the feed screw 12c rotates. The liquid delivery tube 14 is detachably fluidly connected (connected in a state in which the liquid medicine can flow) to the connection port 40, which will be described later, via the liquid delivery hole 16.

The reservoir 12 is not limited to a syringe, and may be, for example, a soft bag or other device capable of storing the liquid medicine. The reservoir 12 may be capable of discharging the liquid medicine by the extrusion unit 13. The extrusion unit 13 may be changed to an appropriate drive unit depending on the shape of the reservoir 12.

The power supply unit 15 supplies the driving power required to drive the medicinal liquid administration device 100. The power supply unit 15 is composed of a battery that serves as a power source for driving, for example, the liquid delivery drive unit 23, and a battery box that houses the battery. The power supply unit 15 is connected to an electrode (not shown) on the circuit board 22. The power supply unit 15 may be disposed inside the lid 21 as a component of the second main body unit 20.

The liquid delivery hole 16 is a needle member having a hollow needle tube and a sharp puncture tip. The base end of the liquid delivery hole 16 is connected to the liquid delivery tube 14, and the tip end is inserted into a connection port 40 provided in the cradle 30. As shown in FIG. 3, the liquid delivery hole 16 is positioned inside an engagement recess 17 provided in the bottom surface portion 11a of the first main body portion 10 so that the tip of the liquid delivery hole 16 does not protrude from the engagement recess 17.

The engagement recess 17 is a substantially circular recess that is recessed in the thickness direction of the housing 11 from the bottom surface 11a (specifically, the second bottom surface 11f) of the first main body 10. The inner peripheral shape and inner dimensions of the engagement recess 17 are set according to the outer shape and outer dimensions of the connection port 40 with which it engages. When the device main body 101 is attached to the cradle 30, the engagement recess 17 engages so as to cover the connection port 40. The engagement recess 17 is located on the second bottom surface 11f at a position that faces the connection port 40 when the device main body 101 is attached to the cradle 30.

<Second main body part>
The second main body 20 has a cover 21, a circuit board 22, and a liquid delivery drive unit 23, and is connected to the first main body 10. The second main body 20 is a portion in which electronic control functions of the drug solution administration device 100 are collectively arranged. The second main body 20 is configured by accommodating electronic control function components such as the circuit board 22 and the liquid delivery drive unit 23 inside the cover 21.

The lid 21 is configured to be detachable from the housing 11 of the first main body 10. The upper surface of the lid 21 forms the top surface of the drug solution administration device 100. Electronic control function components such as the circuit board 22 and the liquid delivery drive unit 23 are attached to the lower surface side of the lid 21.

The liquid delivery drive unit 23 includes a motor 23a and a gear 23b. The motor 23a is a drive source for moving the extrusion unit 13 in a predetermined direction to deliver the liquid medicine in the reservoir 12. The gear 23b is composed of multiple gear stages, and the final gear stage meshes with the gear 12b. This allows the drive force (rotational force) of the motor 23a to be transmitted to the gear 12b via the gear 23b.

The second main body 20 also includes a liquid delivery amount detection unit 24 that can detect the amount of liquid medicine delivered based on the number of rotations of a motor 23a, such as an encoder, a communication unit 25 that is an interface for enabling communication with the outside, and a control unit 26 that is configured by a known microcomputer including a CPU, ROM, RAM, etc. The communication unit 25 and the liquid delivery drive unit 23 operate according to a predetermined program under the control of the control unit 26.

<Cradle>
The cradle 30 includes a cradle body 31 and a connection port 40. The cradle body 31 includes a mounting surface 31a. The connection port 40 is attached to the upper surface of the cradle body 31 (the mounting surface 31a).

The cradle body 31 has an adhesive portion 31b on the underside. The adhesive portion 31b protrudes outward from the support surface portion 31a and is used to attach the cradle 30 to the surface of the living body (the user's skin). The support surface portion 31a is formed in a substantially rectangular shape when viewed from above in the Z direction.

When the device main body 101 is attached to the cradle 30, the bottom surface 101a (bottom surface 11a of the first main body 10) of the device main body 101 is placed on the placement surface 31a. A second attachment portion 31c is provided on the short side (side along the Y direction) of the placement surface 31a, which is attached to the first attachment portion 11d of the first main body 10. The second attachment portion 31c engages the device main body 101 on the cradle 30. The second attachment portion 31c has a hook-shaped engagement protrusion at the tip side that fits with the first attachment portion 11d, and is provided upright in the thickness direction (Z direction) relative to each short side of the placement surface 31a. The second attachment portion 31c engages with the first attachment portion 11d when the device main body 101 is attached to the cradle 30.

The mounting surface portion 31a is composed of a first mounting surface 31e, a second mounting surface 31d, and a second step portion 31f. The first mounting surface 31e and the second mounting surface 31d are each a plane extending along the X direction. The second mounting surface 31d is arranged on the mounting surface portion 31a in the unmounting direction D2, and the first mounting surface 31e is arranged on the mounting direction D1 side of the mounting surface portion 31a. As shown in FIG. 5, the second mounting surface 31d and the first mounting surface 31e are positioned at different levels in the thickness direction (Z direction) of the cradle main body 31, and the second mounting surface 31d is positioned lower (i.e., on the living body surface side) than the first mounting surface 31e. When the device main body 101 is placed on the cradle 30, the first bottom surface 11e of the bottom surface portion 11a is placed on the first mounting surface 31e. When the device main body 101 is placed on the cradle 30, the second bottom surface 11f of the bottom surface portion 11a is placed on the second placement surface 31d.

The second step portion 31f is provided at the boundary portion that divides the first mounting surface 31e and the second mounting surface 31d. The second step portion 31f extends longitudinally along the X direction of the cradle main body 31. As shown in FIG. 4, when the cradle 30 is viewed from the side, the second step portion 31f has a step surface that rises in a substantially vertical direction (Z direction) from the second mounting surface 31d toward the first mounting surface 31e. When the device main body 101 is attached to the cradle 30, the second step portion 31f abuts against the first step portion 11g and functions as an abutment surface that restricts the rotational movement of the device main body 101 in the attachment direction D1.

The mounting surface 31a only needs to have a shape complementary to the bottom surface 101a of the device main body 101 (the bottom surface 11a of the first main body 10) when the device main body 101 and the cradle 30 are fully attached to each other. Therefore, the configuration of the mounting surface 31a is not limited to the configuration described above.

The drug solution administration device 100 has a bottom surface portion 11a and a mounting surface portion 31a that have complementary shapes. More specifically, the bottom surface portion 11a and the mounting surface portion 31a have complementary shapes in the thickness direction as well as in the direction along the surface of the living body. Therefore, when the device body 101 and the cradle 30 are attached to the drug solution administration device 100, the bottom surface portion 101a and the mounting surface portion 31a abut complementarily to prevent deviation in the height direction during rotational movement. In addition, when attaching or detaching the device body 101 to the cradle 30, the user can easily grasp the attachment/detachment direction, and therefore can attach or detach the drug solution administration device 100 in the correct direction. The mounting surface portion 31a is provided with an abutment surface that restricts movement in the attachment direction of the device body 101, which promotes the engagement of the first attachment portion 11d with the second attachment portion 31c.

<Connection port>
5, the connection port 40 is provided on the upper surface of the mounting surface portion 31a of the cradle 30. The connection port 40 includes a port body 41 and a connection portion 42. When the device body 101 is attached to the cradle 30, the connection port 40 is fluidly connected to the liquid supply tube 14 via the connection portion 42.

The connection port 40 is arranged on the mounting surface 31a of the cradle 30 at a position where the device body 101 can rotate approximately parallel to the mounting surface 31a when the device body 101 is temporarily attached to the cradle 30. Specifically, the connection port 40 is arranged near a corner of the mounting surface 31a of the cradle 30. The peripheral surface of the connection port 40 fits into the engagement recess 17 of the device body 101.

The port body 41 is a hollow cylindrical member having an internal space inside, and extends upward (in the Z direction) from the mounting surface 31a of the cradle 30. The port body 41 is sealed by a plug 43.

The port body 41 holds a cannula 50 that is placed in the living body to deliver a medicinal liquid into the living body. The cannula 50 protrudes from the inside of the port body 41 toward the user's body, and at least the tip portion is placed inside the living body. The cannula 50 is made of a resin material such as polyurethane, nylon, or ethylene-tetrafluoroethylene copolymer (ETFE). After the cannula 50 is inserted into the living body, the puncture tool (not shown) is removed from the cradle 30 and discarded.

The connection part 42 is located at the top of the port body 41, facing the liquid supply hole 16 of the device body 101. The connection part 42 is an opening that functions as an introduction port that introduces the medicinal liquid delivered through the liquid supply hole 16 into the connection port 40 when the device body 101 is mounted on the cradle 30, and the upper surface of the connection part 42 is sealed by a stopper 43. The connection part 42 may be attached to the cradle 30 by a known puncture tool (not shown) when the cannula 50 is placed in the living body.

The stopper 43 is disposed above the base end of the cannula 50 inside the port body 41. The surface of the stopper 43 forms the upper surface of the port body 41. The stopper 43 can be made of a material that is flexible and self-sealing. Examples of flexible materials include various rubber materials such as silicone rubber and natural rubber, and various thermoplastic elastomers such as polyurethane, polyester, polyamide, olefin, and styrene. The stopper 43 only needs to be able to seal the connection part 42 and block communication with the outside after the liquid supply hole 16 is removed from the stopper 43. The stopper 43 may be formed as a needleless connector, in which case the liquid supply hole 16 does not need to be needle-shaped.

The drug solution administration device 100 according to the first embodiment is configured to rotate and move the device body 101 relative to the cradle 30 to attach or separate it, with the engagement recess 17 provided on the device body 101 engaged with the connection port 40 of the cradle 30. In the drug solution administration device 100 configured in this way, the bottom surface 101a (bottom surface 11a) of the device body 101 and the mounting surface 31a of the cradle 30 have complementary shapes. In detail, when the drug solution administration device 100 is attached to the device body 101 and the cradle 30, the first bottom surface 11e of the bottom surface 11a abuts against the first mounting surface 31e of the mounting surface 31a, and the second bottom surface 11f of the bottom surface 11a abuts against the second mounting surface 31d of the mounting surface 31a. In addition, when the device body 101 of the drug solution administration device 100 is attached to the cradle 30, the first step 11g of the bottom surface 11a comes into contact with the second step 31f of the mounting surface 31a, thereby determining the position at which the device body 101 is completely attached.

When the device body 101 and the cradle 30 are in the fully attached position, the bottom surface 101a of the device body 101 comes into contact with the mounting surface 31a of the cradle 30, restricting the attachment operation of the drug solution administration device 100. In addition, when the device body 101 is separated from the cradle 30, the separation direction is restricted between the bottom surface 101a and the mounting surface 31a. This allows the device body 101 to be attached to and detached from the cradle 30 in the correct direction. In particular, the drug solution administration device 100 is attached to the abdomen or back of the user, but the attachment location and the orientation of the drug solution administration device 100 are not always constant because they depend on the skin and subcutaneous condition of the user on that day. This reduces damage to the connection part 42 and the second attachment part 31c, etc., that occurs when the user rotates the device body 101 too much relative to the cradle 30, pushes the device body 101 into the cradle 30 with too much force, or removes it.

The drug solution administration device 100 has a bottom surface 101a of the device body 101 and a mounting surface 31a of the cradle 30 that have complementary shapes, so that when the device body 101 is attached to the cradle 30, the attachment position and movement direction are easy to grasp, improving wearability. In addition, by providing such a regulating structure in a position that is not visible from the outside of the drug solution administration device 100, the wearability of the drug solution administration device 100 is improved. In other words, this is preferable for the user because it is possible to minimize structures on the outer surface of the drug solution administration device 100 that may get caught on the user's clothing.

Furthermore, when the device body 101 of the drug solution administration device 100 is attached to the cradle 30, the liquid delivery hole 16 is pierced in the stopper 43 with the engagement recess 17 and the outer periphery of the port body 41 rotatably engaged. This makes it difficult for the puncture points of the liquid delivery hole 16 in the stopper 43 to be scattered. It also reduces damage to the stopper 43 and deterioration of the sealing property of the stopper 43 caused by the liquid delivery hole 16 pierced in the stopper 43 being misaligned during the attachment operation.

<Operation>
Next, the operation of mounting the device body 101 on the cradle 30 in the drug solution administration device 100 according to the first embodiment will be described with reference to FIGS.

As a preliminary step to using the drug solution administration device 100, the user attaches the cradle 30 to the surface of the living body and places the cannula 50 inside the living body using any puncture device. When placing the cannula 50, the user attaches the adhesive part 31b of the cradle 30 to the skin and then inserts the puncture needle and the cannula 50 through the connection part 42. With the cannula 50 left inside the living body, the user removes the puncture needle and the puncture device (not shown) used to insert the puncture needle from the cradle 30.

Next, the user assembles the device main body 101 by connecting the second main body 20 to the first main body 10. As shown in FIG. 6, the user lowers the assembled device main body 101 toward the surface of the cradle 30 (along the Z direction) so as to engage the engagement recess 17 with the connection port 40. At this time, the angle between the long axis of the device main body 101 and the long axis of the cradle 30 as viewed from the Z direction (i.e., the angle of rotation when the device main body 101 moves in the mounting direction D1) is 15° to 135°, more preferably 15° to 90°. At this time, the second mounting portion 31c and the device main body 101 are not overlapped as viewed from the Z direction.

As shown in FIG. 7, the user engages the engagement recess 17 of the device body 101 with the connection port 40 to temporarily attach it. At this time, the liquid supply hole 16 is attached by penetrating the stopper 43. As a result, the connection port 40 forms a liquid medicine flow path (a flow path that connects to the cannula 50 in the connection port 40) that communicates with the liquid supply hole 16, and the liquid medicine can be administered by the liquid medicine administration device 100. In other words, the connection port 40 is in a state in which it can be fluidly connected to the liquid supply hole 16. However, since the device body 101 has not yet been completely attached to the cradle 30, the liquid medicine administration device 100 is not yet activated. In addition, a part of the bottom surface 101a of the device body 101 is in contact with a part of the mounting surface 31a.

From the temporary attachment state shown in FIG. 7, the user rotates the device body 101 in the attachment direction D1, parallel to the surface of the living body, along the arrow in the figure, with the engagement position of the engagement recess 17 and the connection port 40 as the rotation center. At this time, the user rotates the device body 101 to a position where the first step portion 11g of the bottom surface portion 101a of the device body 101 abuts against the second step portion 31f of the cradle 30.

The user rotates the device body 101 until the first step 11g abuts the second step 31f, engaging the first mounting part 11d and the second mounting part 31c. This completes the mounting of the drug solution administration device 100, as shown in FIG. 8. When the user activates the drug solution administration device 100, the liquid delivery drive unit 23 is driven at a predetermined timing to allow the drug solution stored in the reservoir 12 to flow from the liquid delivery hole 16 through the liquid delivery tube 14 into the port body 41. The drug solution that flows into the port body 41 by activating the drug solution administration device 100 is introduced into the living body through the cannula 50.

When removing the device body 101 from the cradle 30, the user releases the engagement between the first mounting part 11d and the second mounting part 31c, and then rotates the device body 101 in the removal direction D2 around the engagement position of the engagement recess 17 and the connection port 40 as the center of rotation. As a result, a part of the bottom surface part 101a of the device body 101 is separated from the mounting surface part 31a of the cradle 30. The user then moves the device body 101 upward. As a result, the device body 101 is completely removed from the cradle 30. After the liquid supply hole 16 that penetrates the plug 43 is removed, the self-sealing plug 43 blocks communication between the inside of the connection port 40 and the outside. Alternatively, when removing the device main body 101 from the cradle 30, the user may release the engagement between the engagement recess 17 and one of the pair of second mounting parts 31c that is closer to the connection port 40, and then lift the device main body 101 in the Z direction to remove it. In this case as well, the first step 11g and the second step 31f restrict displacement in the D1 direction.

[Second embodiment]
Next, a drug solution administration device 110 according to a second embodiment will be described with reference to Figures 9 to 16. In the second embodiment, components having the same functions as those in the first embodiment described above are denoted by the same reference numerals, and detailed descriptions thereof are omitted. Configurations, members, and methods of use that are not specifically mentioned may be the same as those in the above-described embodiment.

The second embodiment described below shows a configuration in which the shape of the bottom surface 111a (bottom surface 11a) of the device main body 111 and the mounting surface 31a of the cradle 30 are partially modified.

<Configuration>
In the drug solution administration device 110 according to the second embodiment, the bottom surface 11a of the first main body 10, which becomes the bottom surface 111a of the device main body 111, is composed of a first bottom surface 11h, a second bottom surface 11k, and a first step portion 11m, as shown in Fig. 10. The bottom surface 11a is a plate surface extending along the X direction and has a shape with a portion cut out, as shown in Fig. 10. The second bottom surface 11k is a plane along the X direction and the Y direction in the cut-out portion of the bottom surface 11a.

The first bottom surface 11h is generally rectangular in plan view, with an engagement recess 17 provided near one of its corners. The engagement recess 17 is recessed into the first bottom surface 11h in the thickness direction of the housing 11. The first bottom surface 11h is also provided with a first guide portion 18 for engaging with a second guide portion 32 (described later) to guide the rotational movement of the device body 111 in the mounting direction D1 and the removal direction D2 (see FIG. 11). The first guide portion 18 is composed of a convex ridge portion that curves at a predetermined curvature along the movement trajectory of the rotational movement of the device body 111 in the mounting direction D1 (removal direction D2).

The first bottom surface 11h is a plane that extends along the X direction on the entire surface excluding the engagement recess 17 and the first guide portion 18. As an example, the first bottom surface 11h is disposed on the bottom surface portion 11a on the side facing the mounting direction D1 of the device main body 101.

The second bottom surface 11k is recessed in the thickness direction of the housing 11 on the bottom surface portion 11a. That is, the second bottom surface 11k is located higher than the first bottom surface 11h when the device body 111 is viewed from the side. As an example, the second bottom surface 11k is located on the bottom surface portion 11a on the side in the removal direction D2 of the device body 111. No engagement recess 17 is located within the area of the first bottom surface 11h.

As shown in FIG. 10, the first bottom surface 11h and the second bottom surface 11k are positioned at different levels in the thickness direction (Z direction) of the housing 11, and the first bottom surface 11h is positioned lower (i.e., closer to the body surface) than the second bottom surface 11k. When the device main body 111 is placed on the cradle 30, the first bottom surface 11h is placed on the first placement surface 31g of the placement surface portion 31a. When the device main body 111 is placed on the cradle 30, the second bottom surface 11k is placed on the second placement surface 31h of the placement surface portion 31a.

The first step portion 11m is provided at the boundary portion that separates the first bottom surface 11h and the second bottom surface 11k. The first step portion 11m is provided along a part of the outer edge portion of the second bottom surface 11k and is substantially L-shaped in a plan view. As shown in FIG. 10, when the first main body portion 10 is viewed from the side, the first step portion 11g has a step surface that falls in a substantially vertical direction (Z direction) from the second bottom surface 11k toward the first bottom surface 11h.

The bottom surface portion 11a only needs to have a shape complementary to the mounting surface portion 31a of the cradle 30 (i.e., a shape complementary to a direction perpendicular to the mounting operation direction) when the device main body 111 and the cradle 30 are fully attached to each other. Therefore, the configuration of the bottom surface portion 11a is not limited to the configuration described above.

The mounting surface portion 31a of the cradle 30 is composed of a first mounting surface 31g, a second mounting surface 31h, and a second step portion 31k. As shown in FIG. 11, the mounting surface portion 31a is a plate surface extending along the X direction, with a portion of the plate surface protruding upward. As shown in FIG. 11, the second mounting surface 31h is a flat surface along the X direction and the Y direction in a portion of the mounting surface portion 31a that protrudes into a substantially rectangular parallelepiped shape. In addition, a connection port 40 is arranged at a corner of the substantially rectangular first mounting surface 31a.

The second mounting surface 31h is a surface of the mounting surface portion 31a that is thicker than the first mounting surface 31g. That is, the second mounting surface 31h is a surface of a portion that protrudes from the first mounting surface 31g in the thickness direction (Z direction) of the housing 11 in an approximately rectangular parallelepiped shape. As shown in FIG. 11, the second mounting surface 31h extends along the X direction from the vicinity of the connection port 40 to the outer edge of the short side that is distal to the connection port 40 on the mounting surface portion 31a. As an example, the second mounting surface 31h is disposed on the mounting surface portion 31a in the unmounting direction D2. As an example, the first mounting surface 31g is disposed on the mounting direction D1 side of the mounting surface portion 31a. Note that the connection port 40 that is not located within the second mounting surface 31h is disposed within the first mounting surface 31g.

As shown in FIG. 11, the first mounting surface 31g and the second mounting surface 31h are positioned at different levels in the thickness direction (Z direction) of the cradle main body 31, and the second mounting surface 31h is positioned higher in the thickness direction than the first mounting surface 31g. The first mounting surface 31g and the second mounting surface 31h are approximately parallel to the surface of the living body. When the device main body 111 is placed on the cradle 30, the first bottom surface 11h of the bottom surface portion 11a is placed on the first mounting surface 31g. When the device main body 111 is placed on the cradle 30, the second bottom surface 11k of the bottom surface portion 11a is placed on the second mounting surface 31h.

The second step portion 31k is provided at the boundary portion that separates the first mounting surface 31g and the second mounting surface 31h. The second step portion 31k is generally L-shaped along the outer edge of the second mounting surface 31h in a portion that rises in a generally rectangular parallelepiped shape from the first mounting surface 31g in the thickness direction (Z direction) of the housing 11. As shown in FIG. 12, when the cradle 30 is viewed from the side, the second step portion 31k has a step surface that rises in a generally vertical direction (Z direction) from the first mounting surface 31g toward the second mounting surface 31h.

The mounting surface 31a only needs to have a shape complementary to the bottom surface 111a of the device main body 111 (the bottom surface 11a of the first main body 10) when the device main body 111 and the cradle 30 are fully attached to each other. Therefore, the configuration of the mounting surface 31a is not limited to the configuration described above.

The mounting surface portion 31a includes a second guide portion 32 that engages with the first guide portion 18. The second guide portion 32 is provided on the mounting surface portion 31a so as to pass from the outer edge along the X direction of the cradle 30 through a part of the second mounting surface 31h and the first mounting surface 31g. The second guide portion 32 is configured as a concave groove that curves with a predetermined curvature along the movement trajectory caused by the rotational movement of the device main body 111. The second guide portion 32 has a shape complementary to the first guide portion 18, and is not particularly limited in shape, etc., as long as it is configured to guide and regulate the mounting operation of the device main body 111 to the cradle 30.

Abutting portions 33 are provided on the outer edge of the mounting surface 31a of the cradle 30 along the X direction to abut against the device body 111 and restrict movement in the mounting direction D1. In detail, the abutting portions 33 are plate-shaped members that stand upright in the thickness direction of the cradle body 31 on the outer edge of the mounting surface 31a on the mounting direction D1 side. When mounting the device body 111 to the cradle 30, the user rotates the device body 111 in the mounting direction D1 until the side of the device body 111 abuts against the abutting portions 33. This allows the user to grasp the end position of the rotation of the device body 111.

The drug solution administration device 110 according to the second embodiment differs in part from the drug solution administration device 100 according to the first embodiment in the manner in which the device body 111 is attached to the cradle 30. In detail, as shown in FIG. 12A, the drug solution administration device 110 engages the engagement recess 17 of the device body 111 with the outer periphery of the connection port 40 to set the device body 111 in a temporary attachment state, and then rotates the device body 111 in the attachment direction D1 to abut the side of the device body 111 against the abutment portion 33. At this time, the first bottom surface 11h of the bottom surface portion 11a is not placed in abutment on the first mounting surface 31g of the mounting surface portion 31a. Also, the second bottom surface 11k of the bottom surface portion 11a is not placed on the second mounting surface 31h of the mounting surface portion 31a. In addition, the first guide part 18 and the second guide part 32 are partially engaged in the stage shown in FIG. 12A, but the top of the first guide part 18 and the bottom of the second guide part 32 are not in contact. The liquid supply hole 16 is not inserted into the plug 43.

12B, the drug solution administration device 110 lowers the device body 111 toward the cradle 30 with the side of the device body 111 abutting against the abutment portion 33, and engages the first mounting portion 11d with the second mounting portion 31c to complete the attachment. As a result, the first bottom surface 11h of the bottom surface portion 11a of the drug solution administration device 110 is placed on the first mounting surface 31g of the mounting surface portion 31a, and the second bottom surface 11k of the bottom surface portion 11a is placed on the second mounting surface 31h of the mounting surface portion 31a. In addition, the top of the first guide portion 18 and the bottom of the second guide portion 32 abut against each other at the stage shown in FIG. 12B. The liquid delivery hole 16 is inserted into the plug 43, and the device body 111 and the cannula 50 are fluidly connected.

The drug solution administration device 110 according to the second embodiment is configured to rotate and move the device body 111 relative to the cradle 30 to attach or separate it, in a state in which the engagement recess 17 provided on the device body 111 is engaged with the connection port 40 of the cradle 30, similar to the drug solution administration device 100 according to the first embodiment. In the drug solution administration device 110 configured in this way, the bottom surface 111a (bottom surface 11a) of the device body 111 and the mounting surface 31a of the cradle 30 have complementary shapes. In detail, when the attachment of the device body 111 and the cradle 30 is completed, the first bottom surface 11h of the bottom surface 11a abuts against the first mounting surface 31g of the mounting surface 31a, and the second bottom surface 11k of the bottom surface 11a abuts against the second mounting surface 31h of the mounting surface 31a. In addition, the drug solution administration device 110 includes an abutment portion 33 that abuts against the side of the device body 111 that has been rotated in the mounting direction D1 with the first guide portion 18 and the second guide portion 32 engaged when the device body 111 is mounted on the cradle 30.

Therefore, when the device body 111 and the cradle 30 are attached to the drug solution administration device 110, the bottom surface 111a of the device body 111 is brought into contact with the mounting surface 31a of the cradle 30, and the side of the device body 111 is rotated parallel to the surface of the living body until it abuts the abutment portion 33 while engaging the first guide portion 18 and the second guide portion 32, thereby preventing displacement in the height direction and the lateral direction during rotation. Therefore, the drug solution administration device 110 can be stably attached by rotating the device body 111 with the bottom surface 111a of the device body 111 abutting the mounting surface 31a of the cradle 30. This restricts the height direction during rotational attachment, thereby reducing damage to the stopper 43 caused by the liquid delivery hole 16 during attachment. In addition, the drug solution administration device 110 has a bottom surface 111a of the device body 111 and a mounting surface 31a of the cradle 30 that have complementary surface shapes in the thickness direction as well as in the direction along the surface of the living body. This not only stabilizes the posture of the device body 111 while moving it when the device body 111 is attached to the cradle 30, but also makes it easier to grasp the attachment position and movement direction. Furthermore, since the drug solution administration device 110 has a contact portion 33 along at least a part of the outer periphery of the side surface, the attachment completion position of the device body 111 can be easily grasped. In this case, even if the drug solution administration device 110 is attached to a position that the user cannot directly see, such as the user's abdomen or back, the user can confirm the operation direction by touching the contact portion 33 located on the side surface of the drug solution administration device 110, which is useful.

<Operation>
Next, the operation of mounting the device body 111 on the cradle 30 in the drug solution administration device 110 according to the second embodiment will be described with reference to FIGS.

As a preliminary step to using the drug solution administration device 110, the user attaches the cradle 30 to the surface of the living body and places the cannula 50 inside the living body. When placing the cannula 50, the user attaches the adhesive part 31b of the cradle 30 to the skin, and then inserts the cannula 50 together with the puncture needle into the living body via the connection part 42. With the cannula 50 left inside the living body, the user removes the puncture needle and the puncture device (not shown) used to insert the puncture needle from the cradle 30.

Next, the user assembles the device main body 111 by connecting the second main body 20 to the first main body 10. As shown in FIG. 13, the user lowers the assembled device main body 111 in the Z direction relative to the cradle 30 so that the inner circumference of the engagement recess 17 engages with the outer circumference of the connection port 40. At this time, the angle between the long axis of the device main body 111 and the long axis of the cradle 30 as viewed from the Z direction (i.e., the rotation angle required for the device main body 111 to move in the mounting direction D1) is 15° to 135°, more preferably 15° to 90°. At this time, the second mounting portion 31c and the device main body 111 are positioned so as not to overlap as viewed from the Z direction.

The user engages the engagement recess 17 of the device body 111 with the connection port 40 to temporarily attach it. At this time, the liquid supply hole 16 is attached by penetrating the stopper 43. As a result, the connection port 40 forms a liquid medicine flow path (a flow path that connects to the cannula 50 in the connection port 40) that communicates with the liquid supply hole 16, and the liquid medicine can be administered by the liquid medicine administration device 110. In other words, the connection port 40 is in a state of being fluidly connected to the liquid supply hole 16. However, since the device body 111 has not yet been completely attached to the cradle 30, the liquid medicine administration device 110 is in an unactivated state. In addition, the first guide portion 18 and the second guide portion 32 are partially engaged.

As shown in FIG. 14, the user rotates the device body 111 from the temporary attachment state in the attachment direction D1 along the arrow in the figure, with the engagement position of the engagement recess 17 and the connection port 40 as the rotation center. At this time, the user rotates the device body 111 to a position where the side of the device body 111 abuts against the abutment portion 33, as shown in FIG. 15.

Next, the user lowers the device body 111 toward the cradle 30, engaging the first mounting part 11d and the second mounting part 31c. At this time, the liquid supply hole 16 is inserted into the stopper body 43, and the device body 111 and the cannula 50 are fluidly connected. As a result, the drug solution administration device 110 is in a state of complete installation, as shown in FIG. 16. If the user starts the drug solution administration device 110, the liquid supply drive unit 23 is driven at a predetermined timing to cause the drug solution stored in the reservoir 12 to flow from the liquid supply hole 16 to the port body 41 via the liquid supply tube 14. The drug solution that flows into the port body 41 by starting the drug solution administration device 110 is introduced into the living body through the cannula 50. In addition, in the temporary installation state, the liquid supply hole 16 may be punctured and inserted into the stopper body 43, and the device body 111 may be rotated in a state in which the engagement recess 17 and the connection port 40 are engaged. In this case, after completing the rotational movement operation, the liquid delivery hole 16 can be reliably punctured and inserted into the plug 43 by pushing the device body 111 into the cradle 30.

When removing the device body 111 from the cradle 30 while using the drug solution administration device 110, the user releases the engagement between the first mounting part 11d and the second mounting part 31c, and then slightly lifts the device body 111. As a result, the bottom surface part 111a of the device body 111 moves away from the mounting surface part 31a of the cradle 30. Next, the user rotates the device body 111 in the removal direction D2, with the engagement position of the engagement recess 17 and the connection port 40 as the center of rotation. This releases the engagement between the first guide part 18 and the second guide part 32. After that, the user moves the device body 111 upward. This causes the device body 111 to be completely removed from the cradle 30. After the liquid supply hole 16 is removed, the connection port 40 is self-sealed by the plug 43, and communication with the outside is blocked.

[Variations]
Next, modified examples of the drug solution administration device 100 according to the first embodiment and the drug solution administration device 110 according to the second embodiment will be described with reference to Figures 17 to 20. Note that in the following description, a configuration in which the modified example is applied to the drug solution administration device 100 according to the first embodiment will be described, but the modified example configuration can also be applied to the drug solution administration device 110 according to the second embodiment.

The modified example of the drug solution administration device 100 further includes a guide member 200 for guiding the mounting operation by rotational movement. FIG. 17 shows a configuration in which the drug solution administration device 100 according to the first embodiment is provided with a guide member 200.

As shown in FIG. 17, the guide member 200 has a side wall portion 201 that stands along a part of the outer edge of the mounting surface portion 31a of the cradle 30, and a covering portion 202 that abuts against the top of the side wall portion 201 and extends along the X direction so as to cover a part of the mounting surface portion 31a of the cradle 30.

The side wall 201 is provided continuously on the long side at the back side of the outer edge of the placement surface 31a in the mounting direction D1 and on the short side distal from the connection port 40. Therefore, the cradle 30 is in a state where the side from which the device body 101 starts to rotate is open. The device body 101 is capable of rotating in the mounting direction D1 from a state in which it is temporarily attached to the connection port 40. The height of the side wall 201 is preferably set so as to improve mounting ease without impairing the guide function of the guide member 200. Specifically, the side wall 201 is preferably set to a height such that, when the device body 101 is completely attached to the cradle 30, there is a slight gap between the side wall 201 and the upper surface (top surface) of the lid 21 of the second main body 20 so that the side wall 201 does not come into contact with the upper surface.

The covering portion 202 is provided so as to partially cover the mounting surface portion 31a of the cradle 30 from above. The covering portion 202 has a shape that covers the upper part of the mounting surface portion 31a except for the area that may come into contact with the device main body 101 when the device main body 101 is temporarily attached to the connection port 40.

The drug solution administration device 100 includes a guide member 200, which makes it easier to attach the device body 101 to the cradle 30 by rotating it using the guide member 200 as a guide. When the device body 101 is rotated along the guide member 200, it can be attached as if it were being stored in the guide member 200, which is roughly box-shaped with an opening.

The guide member 200 is not limited to the shape shown in FIG. 17, as long as it has a shape that serves as a guide without interfering with the mounting operation of the device body 101 when mounting the device body 101 on the cradle 30.

The drug solution administration device 100 to which the configuration of the modified example is applied can mount the device body 101 on the cradle 30 as follows. In detail, as shown in FIG. 18, the user temporarily mounts the device body 101 by engaging the engagement recess 17 of the device body 101 with the connection port 40 of the cradle 30. At this time, the guide member 200 is provided so that a portion of the mounting surface portion 31a is exposed, so that it does not get in the way when engaging the engagement recess 17 of the device body 101 with the connection port 40 of the cradle 30. In addition, the guide member 200 is shaped to fit along and cover a portion of the upper surface of the device body 101, so that the device body 101 can be securely held on the cradle 30.

As shown in FIG. 19, the user rotates the device body 101 from the temporary attachment state in the attachment direction D1 relative to the cradle 30 along the arrow in the figure, with the engagement position of the engagement recess 17 and the connection port 40 as the rotation center. At this time, the user rotates the device body 101 to a position where the side of the device body 101 abuts against the side wall portion 201 of the guide member 200 so that the outer circumferential surface of the device body 101 is stored inside the guide member 200. This allows the user to rotate the device body 101 with the connection between the engagement recess 17 and the connection port 40 in a stable state. When the device body 101 moves to a position where the side abuts against the side wall portion 201 of the guide member 200, the first step portion 11g and the second step portion 31f abut, so that the rotational movement of the device body 101 is restricted.

The user rotates the device body 101 until the first step 11g abuts the second step 31f, and then engages the first attachment part 11d with the second attachment part 31c. This completes the attachment of the drug solution administration device 100, as shown in FIG. 20. When the user activates the drug solution administration device 100, the liquid delivery drive unit 23 is driven at a predetermined timing to allow the drug solution stored in the reservoir 12 to flow from the liquid delivery hole 16 through the liquid delivery tube 14 into the port body 41. The drug solution that flows into the port body 41 by activating the drug solution administration device 100 is introduced into the living body through the cannula 50.

[Effects]
As described above, the drug solution administration device 100, 110 according to the present embodiment includes a device body 101, 111 including a reservoir 12 for storing the drug solution, a liquid delivery drive unit 23 for delivering the drug solution from the reservoir 12, a liquid delivery tube 14 through which the drug solution delivered from the reservoir 12 flows, and a liquid delivery hole 16 communicating with the liquid delivery tube 14, a mounting surface 31a on which the bottom surface 101a, 111a (bottom surface 11a) of the device body 101, 111 is placed, and a cradle 30 to which a connection port 40 for holding a cannula 50 to be inserted into a living body is attached and which is attached to the living body, and the device is a device in which the liquid delivery hole 16 and the connection port 40 are detachably fluid-connected. In the drug solution administration device 100, 110 having such a configuration, the mounting surface 31a has a shape complementary to the bottom surface 101a, 111a.

In addition, in the drug solution administration device 100, 110 according to this embodiment, the device body 101, 111 may be configured to have an engagement recess 17 on the bottom surface 101a, 111a (bottom surface 11a) that has a liquid delivery hole 16 on the inside and is capable of engaging with the connection port 40, and to be attached to the cradle 30 by rotating and moving the engagement recess 17 in the attachment direction D1 relative to the cradle 30 with the engagement recess 17 engaged with the connection port 40.

In addition, in the drug solution administration device 100, 110 according to this embodiment, the connection port 40 may be provided with a plug 43 having a self-sealing ability, and the liquid delivery hole 16 may be configured to penetrate the plug 43 and be fluidly connected to the connection port 40.

In the thus configured drug solution administration device 100, 110, the bottom surface 101a, 111a of the device body 101, 111 and the mounting surface 31a of the cradle 30 have complementary shapes, so that, for example, if the device body 101, 111 is slid and attached with the bottom surface 101a, 111a and the mounting surface 31a in contact with each other, it is possible to prevent misalignment during attachment. Therefore, the drug solution administration device 100 can reduce damage to the stopper 43 caused by the liquid delivery hole 16. Furthermore, in the drug solution administration device 100, 110, the bottom surface 101a, 111a of the device body 101, 111 and the mounting surface 31a of the cradle 30 have complementary shapes, so that when the device body 101, 111 is attached to the cradle 30, it is easy to grasp the attachment position and movement direction, improving attachment. This is particularly useful because the drug administration devices 100 and 110 are often worn on the abdomen or back of the user.

In addition, in the drug solution administration device 100, 110 according to this embodiment, the mounting surface 31a has a regulating portion that abuts against the bottom surface 101a, 111a of the device body 101, 111 to regulate the movement of the device body 101, 111 during installation, and the regulating portion may be configured to have a surface shape perpendicular to the mounting direction of the device body 101, 111 and to regulate the device body 101, 111 from moving beyond the completed installation position relative to the mounting surface 31a.

According to the thus configured medicinal liquid administration device 100, 110, when the device main body 101, 111 and the cradle 30 are attached by rotating the device main body 101, 111 parallel to the surface of the living body, the attachment can be completed in the correct position. This can reduce the load on the connection part 42 and the second attachment part 31c caused by the user rotating the device main body 101, 111 too much relative to the cradle 30, forcing the device main body 101, 111 into the cradle 30, or removing the device main body 101, 111, and thus the damage of the plug body 43 due to the liquid delivery hole 16. In addition, since the restricting part that restricts the attachment/detachment movement is provided on the contact surface between the device main body 101, 111 and the cradle 30 as a complementary structure, it is not exposed on the upper surface (outer surface) of the medicinal liquid administration device 100, 110 when the attachment of the device main body 101, 111 is completed. Therefore, the user's clothes are less likely to get caught when the medicinal liquid administration device 100, 110 is attached, improving the wearability.

In addition, in the drug solution administration device 100 according to this embodiment, the bottom surface portion 101a (bottom surface portion 11a) has a first bottom surface 11e, a second bottom surface 11f that is disposed lower than the first bottom surface 11e in the thickness direction of the bottom surface portion 11a, and a first step portion 11g that is provided at the boundary portion between the first bottom surface 11e and the second bottom surface 11f and rises from the second bottom surface 11f toward the first bottom surface 11e. 1a has a first mounting surface 31e on which the first bottom surface 11e is placed, a second mounting surface 31d on which the second bottom surface 11f is placed, and a second step portion 31f provided at the boundary between the first mounting surface 31e and the second mounting surface 31d and rising from the second mounting surface 31d toward the first mounting surface 31e, and the first mounting surface 31e is disposed above the second mounting surface 31d in the thickness direction of the mounting surface portion 31a. In addition, the device main body 101 may be configured to be mounted on the cradle 30 by rotating and moving in the mounting direction D1 relative to the cradle 30 with the engagement recess 17 engaged with the connection port 40, so that the first bottom surface 11e is placed on the first mounting surface 31e and the second bottom surface 11f is placed on the second mounting surface 31d, with the first step portion 11g and the second step portion 31f abutting against each other.

According to the medicinal liquid administration device 100 configured in this manner, when the device body 101 and the cradle 30 are attached, the device body 101 is rotated until the bottom surface 101a (bottom surface 11a) and the mounting surface 31a of the cradle 30 come into contact, thereby reducing misalignment in the rotational direction during rotation and the load on the second attachment portion 31c. The medicinal liquid administration device 100 can be stably attached by rotating the device body 101 with the bottom surface 101a and the mounting surface 31a of the cradle 30 in contact with each other, reducing damage to the plug 43 caused by the liquid delivery hole 16. Furthermore, the drug solution administration device 100 has a complementary shape between the bottom surface 101a of the device body 101 and the mounting surface 31a of the cradle 30, so when attaching the device body 101 to the cradle 30, it is easy to grasp the attachment position and movement direction, improving attachment ease.

In addition, in the medicinal liquid administration device 100 according to this embodiment, the regulating portion may be configured to have a surface that is not exposed on the outer surface of the medicinal liquid administration device 100 when the device body is in a fully attached state.

The drug solution administration device 100 configured in this manner is less likely to get caught on the user's clothing, etc., improving wearability.

In addition, in the drug solution administration device 110 according to this embodiment, the bottom surface portion 111a (bottom surface portion 11a) has a first bottom surface 11h, a second bottom surface 11k that is arranged higher than the first bottom surface 11h in the thickness direction of the bottom surface portion 11a, and a first guide portion 18 that is provided on the first bottom surface 11h so as to follow the movement trajectory due to the rotational movement of the device body 111, and the mounting surface portion 31a has a first mounting surface 31g on which the first bottom surface 11h is placed, a second mounting surface 31h that is arranged higher than the first mounting surface 31g in the thickness direction of the mounting surface portion 31a and on which the second bottom surface 11k is placed, and a second guide portion 32 that is provided from the second mounting surface 31h to the first mounting surface 31g so as to follow the movement trajectory due to the rotational movement of the device body 111. The device main body 111 may also be configured to be mounted on the cradle 30 with the first bottom surface 11h placed on the first mounting surface 31g and the second bottom surface 11k placed on the second mounting surface 31h by rotating and moving in the mounting direction D1 relative to the cradle 30 and then lowering with the engagement recess 17 engaged with the connection port 40 and the first guide portion 18 engaged with the second guide portion 32.

According to the thus configured medicinal liquid administration device 110, when the device body 111 and the cradle 30 are attached, the bottom surface 111a (bottom surface 11a) of the device body 111 is abutted against the mounting surface 31a of the cradle 30, and the side of the device body 111 is rotated until it abuts against the abutment portion 33 while engaging the first guide portion 18 and the second guide portion 32, thereby preventing vertical and lateral displacement during rotation. Therefore, even if the medicinal liquid administration device 110 is attached by rotating the device body 111 with the bottom surface 111a of the device body 111 abutting against the mounting surface 31a of the cradle 30, damage to the plug 43 due to the liquid delivery hole 16 can be reduced. Furthermore, the drug solution administration device 110 has a complementary shape between the bottom surface 111a of the device body 111 and the mounting surface 31a of the cradle 30, so when attaching the device body 111 to the cradle 30, it is easy to grasp the attachment position and movement direction, improving attachment ease.

In addition, in the drug solution administration device 110 according to this embodiment, the mounting surface portion 31a may be configured to have an abutment portion 33 that abuts against the side of the device body 111 to restrict the rotational movement of the device body 111.

When the drug solution administration device 110 is configured in this manner, the user rotates the device body 111 in the mounting direction D1 when mounting the device body 111 to the cradle 30, and moves the device body 111 to a position where the side of the device body 111 abuts against the abutment portion 33. This allows the user to grasp the end position of the rotation of the device body 111.

In addition, in the drug solution administration device 100, 110 according to this embodiment, the device body 101, 111 may be configured to have a first mounting part 11d on the side, and the cradle 30 may be configured to have a second mounting part 31c that engages with the first mounting part 11d.

With the thus configured drug solution administration device 100, 110, when the device main body 101, 111 is attached to the cradle 30, the first attachment part 11d and the second attachment part 31c are engaged to maintain a stable attachment state, so that the two do not separate during use and can be used safely.

In addition, in the drug solution administration device 100, 110 according to this embodiment, the cradle 30 may be configured to include a guide member 200 that guides the rotational movement of the device body 101, 111 in the mounting direction D1.

With the medicinal solution administration device 100, 110 configured in this manner, when the device body 101, 111 is attached to the cradle 30 by rotating and moving it, it is possible to attach it by rotating and moving it using the guide member 200, making it easier to attach.

10 First body portion,
11 Housing (11a bottom surface portion, 11d first mounting portion, 11e, 11h first bottom surface, 11f, 11k second bottom surface, 11g, 11m first step portion)
12 reservoir,
14 Liquid delivery tube,
16 liquid delivery hole,
17 engagement recess,
18 first guide portion,
20 second main body portion,
23 Liquid delivery drive unit,
30 cradle,
31 Cradle body (31a mounting surface portion, 31c second mounting portion, 31e, 31g first mounting surface, 31d, 31h second mounting surface, 31f, 31k second step portion),
32 second guide portion,
33 contact portion,
40 connection port,
42 connection part,
43 plug body,
50 cannula,
100, 110 Drug solution administration device,
101, 111 device main body (101a, 111a bottom part),
D1 mounting direction,
D2 Undocking direction.

Claims (9)

a device body including a reservoir for storing a liquid medicine, a liquid delivery drive unit for delivering the liquid medicine from the reservoir, a liquid delivery tube through which the liquid medicine delivered from the reservoir flows, and a liquid delivery hole communicating with the liquid delivery tube;
a mounting surface portion on which the bottom surface portion of the device body is placed, and a cradle to which a connection port for holding a cannula to be inserted into a living body is attached and which is attached to the living body,
A drug solution administration device in which the liquid delivery hole and the connection port are detachably fluidly connected,
The mounting surface portion has a shape complementary to the bottom surface portion,
The cradle is provided with a guide member that guides the rotational movement of the device body in the mounting direction of the drug solution administration device. the mounting surface portion has a restricting portion that abuts against the bottom surface portion of the device body to restrict the mounting movement of the device body,
The drug solution administration device according to claim 1 , wherein the regulating portion has a surface shape perpendicular to an attachment direction of the device body and regulates the device body from moving beyond a complete attachment position relative to the placement surface portion. the device body includes an engagement recess on the bottom surface, the engagement recess having the liquid supply hole formed therein and capable of engaging with the connection port;
The drug solution administration device according to claim 1 or 2, configured to be mounted on the cradle by rotating and moving the drug solution administration device in a mounting direction relative to the cradle with the engagement recess engaged with the connection port. the bottom surface portion has a first bottom surface, a second bottom surface disposed lower than the first bottom surface in a thickness direction of the bottom surface portion, and a first step portion provided at a boundary portion between the first bottom surface and the second bottom surface and rising from the second bottom surface toward the first bottom surface,
the mounting surface portion has a first mounting surface on which the first bottom surface is placed, a second mounting surface that is disposed above the first mounting surface in a thickness direction of the mounting surface portion and on which the second bottom surface is placed, and a second step portion that is provided at a boundary portion between the first mounting surface and the second mounting surface and rises from the first mounting surface toward the second mounting surface,
The drug solution administration device of claim 3, wherein the device main body is rotated in the mounting direction relative to the cradle with the engagement recess engaged with the connection port, so that the first bottom surface is placed on the first mounting surface and the second bottom surface is placed on the second mounting surface, with the first step portion and the second step portion abutting and mounted on the cradle. The drug solution administration device according to any one of claims 2 to 4, wherein the regulating portion is formed of a surface that is not exposed on the outer surface of the drug solution administration device when the device body is in a fully attached state. the bottom surface portion has a first bottom surface, a second bottom surface disposed higher than the first bottom surface in a thickness direction of the bottom surface portion, and a first guide portion provided on the first bottom surface so as to follow a movement path caused by a rotational movement of the device body,
the placement surface portion has a first placement surface on which the first bottom surface is placed, a second placement surface that is disposed above the first placement surface in a thickness direction of the placement surface portion and on which the second bottom surface is placed, and a second guide portion that is provided from the second placement surface to the first placement surface so as to follow a movement path caused by a rotational movement of the device main body,
The drug solution administration device of any one of claims 1 to 3, wherein the device main body is attached to the cradle with the first bottom surface placed on the first mounting surface and the second bottom surface placed on the second mounting surface by rotating and moving in the mounting direction relative to the cradle and then lowering with the engagement recess engaged with the connection port and the first guide portion engaged with the second guide portion, so that the first bottom surface is placed on the first mounting surface and the second bottom surface is placed on the second mounting surface. The drug solution administration device according to claim 6, wherein the mounting surface portion has an abutment portion that abuts against a side surface of the device body to restrict rotational movement of the device body. the device body includes a first mounting portion on a side surface,
The drug solution administration device according to any one of claims 1 to 7, wherein the cradle is provided with a second mounting portion that engages with the first mounting portion. The connection port includes a self-sealing plug,
The drug solution administration device according to any one of claims 1 to 8, wherein the liquid delivery hole penetrates the plug and is fluidly connected to the connection port.